Home 9 Home video 9 What role does the procedural or clinical complexity have in the decision of antithrombotic therapy? – Professor Jan Steffel

What role does the procedural or clinical complexity have in the decision of antithrombotic therapy? – Professor Jan Steffel

June 1, 2020

Dr Jan Steffel MD FESC FEHRA FHRS: Professor and Vice Chairman of the Department of Cardiology, Senior Consultant, Division of Electrophysiology & Cardiac Devices, University Hear Center Zurich, Switzerland

Episode 4: Dr. Steffel; a lead author of the latest EHRA Practical Guide, answers the following question in this video series: What role does the procedural or clinical complexity have in the decision of antithrombotic therapy?

 

Disclosure Statement: Dr. Steffel has received consultant and / or speaker fees from Abbott, Amgen, Astra-Zeneca, Bayer, Berlin Chemie / Menarini, Biosense Webster, Biotronik, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Medscape, Medtronic, Merck/MSD, Novartis, Pfizer, Sanofi-Aventis, WebMD, and Zoll. He reports ownership of CorXL. Dr. Steffel has received grant support through his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, Daiichi Sankyo, and Medtronic.

0 Comments

Newsletter

Keep up to date with our latest
articles and journals